Ind-Swift gets Japan regulator's nod for 2 drugs

Ind-Swift Laboratories has received approval from the Japanese Government's pharmaceutical and medical devices agency (PMDA) for the supply of Pioglitazone and Risedronate Sodium from its manufacturing facilities at Derabassi in Punjab. With the approval, the company targets a market share of 15-20 per cent for these products by 2013.

 The market for Pioglitazone, an anti-diabetic drug, is estimated at about $2.8 billion while that of Risedronate Sodium, a drug for Osteoporosis, is pegged at $1.6 billion. The company has already filed four DMFs (drug master files) in Japan including that of Atorvastatin, which commands a $12 billion market. It expects PMDA approval soon. It has filed 302 DMFs so far with various regulatory authorities.